| 摘要 |
Abnormal tissue or malignant organelles within such tissue are destroyed by alpha particles emitted by radionuclide cores that are linked to the abnormal tissue. Targeted radionuclide beads each includes an alpha emitter radionuclide core (12) to which a plurality of antibody linking sites (14) are coupled. Surrounding the linking sites and radionuclide core is a polymeric shell (16) that absorbs alpha particles emitted by the core. A reagent (18) is applied to or included within the polymeric shell. Depending upon the material used for the reagent, it is activated by light of a particular waveband that is selectively applied after antibody linking sites (20) on the exterior of the shell have linked the targeted radionuclide to abnormal tissue in the body of a patient. Certain reagents are activated by light in a waveband corresponding to an absorption waveband of the reagent, while other types of reagents are activated by ultrasonic energy applied from an ultrasound source. When thus activated, the reagent causes fragmentation of the polymeric shell, enabling the alpha particles to pass into the abnormal tissue to which the radionuclide core becomes linked. The alpha particles destroy the abnormal tissue. It is also contemplated that the radionuclide core may instead emit beta particles, which though less toxic than alpha particles, can still destroy the targeted abnormal tissue. |
